Advertisement
Conference Call
Genesis Pharmaceuticals management will host a conference call at 10:00a.m. Eastern on Friday, May 16, 2008 to discuss financial results for thethird quarter of its fiscal year 2008. The conference call will include Mr.Cao Wubo, Chairman and CEO, Mr. Haibo Xu, COO, and Ms Elsa Sung, CFO. Toparticipate in this live conference call, please dial the following numberfive to ten minutes prior to the scheduled conference call time: (888)482-0024. International callers should call (617) 801-9702. The ConferencePasscode is 514 344 81. If you are unable to participate in the call at thattime, replay of the conference call will be available from Friday, May 16 at12:00 p.m. EST until Friday, May 30. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The ConferencePasscode is 91325898.
Advertisement
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engagedin the research, development, production, marketing and sales ofpharmaceutical products in the People's Republic of China. Its operations arelocated in Northeast China in an Economic Development Zone in Laiyang City,Shandong province. Genesis is a major pharmaceutical company in Chinaproducing both western and Chinese herbal-based medical drugs in tablet,capsule and granule form. The Company maintains a representative office inthe U.S. For more information, refer to http://www.Genesis-China.net .
Safe Harbor Statement
Certain statements in this press release that are not historical facts are"forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are not guarantees of futureperformance and are subject to risks and uncertainties that could cause theCompany's actual results and financial position to differ materially fromthose included within the forward-looking statements. Forward-lookingstatements involve risks and uncertainties, including those relating to theCompany's ability to introduce, manufacture and distribute new drugs. Actualresults may differ materially from predicted results, and reported resultsshould not be considered as an indication of future performance. Thepotential risks and uncertainties include, among others, the Company's abilityto obtain raw materials needed in manufacturing, the continuing employment ofkey employees, the failure risks inherent in testing any new drug, thepossibility that regulatory approvals may be delayed or become unavailable,patent or licensing concerns that may include litigation, direct competitionfrom other manufacturers and product obsolescence. More information about thepotential factors that could affect the Company's business and financialresults is included in the Company's filings, available via the United StatesSecurities and Exchange Commission.For more information, please contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung, CFO Tel: +1-954-727-8436 Email: [email protected] Web: http://www.genesis-china.net CCG Elite Investor Relations, Inc. Mr. Crocker Coulson, President Tel: +1-646-213-1915 Email: [email protected] Web: http://www.ccgelite.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
